Digbi Health Launches Digbi Digestive™, the First Gut Microbiome and Genetic-Based Digital Care Program for IBS and Functional Digestive Disorders
A precision care program to improve, reverse and monitor gastrointestinal and functional bowel disorders affecting 70 million Americans, by prescribing food and lifestyle as medicine.
MOUNTAIN VIEW, Calif., June 16, 2021 /Digbi Newswire/ -- Research links the gut microbiome to mental health, sleep disorders, chronic pain, inflammatory digestive and skin illnesses, and chronic lifestyle illnesses including diabetes and obesity.
Digbi Health, the first company with a clinically proven digital genetics and gut microbiome therapeutic platform, today launched Digbi Digestive™, a precision care program designed to improve, reverse and monitor gastrointestinal and functional bowel disorders by prescribing food and lifestyle as medicine.
Digbi Digestive was launched on the basis of a real-world outcomes study of members reversing digestive disorders.
Who these disorders affect
Many functional gastrointestinal disorders disproportionately impact women. Functional digestive disorders, including IBS, affect approximately 70 million Americans.
How the program works
Digbi Digestive begins by analyzing a member's genetics, gut microbiome, meals, habits, and clinical markers of sugar and fat in the blood, in order to isolate inflammatory interactions and develop a deeper understanding of the metabolic pathways involved. Care is then personalized to what that analysis finds.
About Digbi Health
Digbi Health is the precision biology care company unifying metabolic and inflammatory care — including obesity, cardiometabolic, gastrointestinal, and inflammatory disorders. These illnesses share a root cause: a mismatch between an individual's biology and the one-size-fits-all lifestyle guidance they've been given. Digbi combines the gut microbiome, genetics, advanced blood biomarkers, and continuous digital health data to build a unique biological profile for each individual and identify what is driving their disease. AI then personalizes lifestyle treatment and, when needed, clinical treatment, delivered through the first precision-biology AI-orchestrated national telehealth platform. Through Digbi Labs, we invest in our vision of making chronic illness optional and advancing healthspan — partnering with leading universities, pharmaceutical companies, and scientific and clinical laboratories, running distributed human trials and publishing peer-reviewed research on genetics, the gut microbiome, and the use of AI to deliver care that is safe, cost-effective, and accessible. Digbi's healthcare cost reduction is documented in multiple peer-reviewed actuarial claims studies. Digbi is accessible to 30 million individuals through more than 300 employers and health plans.
SOURCE Digbi Health
- IBS
- Digestive Health
- Gut Microbiome
- Genetics
- Product Launch